LONDON, - British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's ...

Chief Minister Devendra Fadnavis on Wednesday reviewed plans for the 2027 Kumbh Mela to be held in Nashik. The meeting was attended by Water Resources Minister Girish Mahajan, officials from 38 ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other best vaccine stocks to buy now. On February 24, CNBC reported that President Trump declared that ...

The next Poorna Kumbh Mela is scheduled to take place in Nashik, Maharashtra, in 2027, after 12 years in the city. Nashik, known for its deep spiritual and mythological significance, will host the ...

Nashik: A woman was killed, and five others were seriously injured after a truck crashed into vehicles in the ghat section of a national highway in Maharashtra's Nashik district, police said on ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its ...

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90. The company’s shares opened today at p1,443. ...

The shares of GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma) jumped over 15 percent to trade at Rs 2,684 apiece on February 18, extending gains for the second straight session after releasing ...

GlaxoSmithKline share price jumped more than 17% on Tuesday and extended its surge for the third consecutive session. GlaxoSmithKline shares spiked as much as 17.69% to ₹2,744.95 apiece on the ...

A team of senior officials from Nashik on Monday arrived in Prayagraj to prepare for successfully organising the Nashik-Trimbakeshwar Kumbh 2027. The 20-member team will closely examine the ...

GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...

The Food and Drug Administration on Friday gave a green light to a new meningococcal vaccine from GSK. Dubbed Penmenvy, the “5-in-1” shot is approved for people aged 10 through 25 years old and ...